Drug intelligence / Profile preview

adebrelimab + nab-paclitaxel + gemcitabine

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AG-Jin Xu-pancreatic cancer refers to a combination therapy regimen consisting of the PD-L1 inhibitor adebrelimab and the chemotherapy doublet AG (nab-paclitaxel and gemcitabine). This regimen is being investigated in a Phase II clinical trial led by Jin Xu at Fudan University Shanghai Cancer Center for the treatment of unresectable locally advanced or metastatic pancreatic cancer. Adebrelimab is a humanized monoclonal antibody that targets Programmed Cell Death Ligand 1 (PD-L1), preventing its binding to PD-1 and B7.1 to enhance the immune response against tumor cells. Nab-paclitaxel is an albumin-bound formulation of paclitaxel that promotes microtubule assembly and stability, leading to cell cycle arrest, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. The combination aims to leverage the synergistic effects of chemotherapy-induced immunogenic cell death and immune checkpoint inhibition.

Brand names: AiruikaAbraxaneGemzar
Other names: Adebrelimab plus AGAdebrelimab + nab-paclitaxel + gemcitabineAG-Jin Xu-pancreatic cancer

Targets

TUBB (Tubulin (alpha and beta subunits))DNACD274 (Programmed cell death protein 1 ligand 1)RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on adebrelimab + nab-paclitaxel + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + nab-paclitaxel + gemcitabine.

Explore the full profile